ATE309345T1 - Antitumor antisense sequenzen gegen h1 und r2 verbindungen von ribonukleotide reductase - Google Patents

Antitumor antisense sequenzen gegen h1 und r2 verbindungen von ribonukleotide reductase

Info

Publication number
ATE309345T1
ATE309345T1 AT97932690T AT97932690T ATE309345T1 AT E309345 T1 ATE309345 T1 AT E309345T1 AT 97932690 T AT97932690 T AT 97932690T AT 97932690 T AT97932690 T AT 97932690T AT E309345 T1 ATE309345 T1 AT E309345T1
Authority
AT
Austria
Prior art keywords
ribonucleotide reductase
compounds
antisense sequences
sequences against
nucleotides
Prior art date
Application number
AT97932690T
Other languages
German (de)
English (en)
Inventor
Jim A Wright
Aiping H Young
Original Assignee
Genesense Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesense Technologies Inc filed Critical Genesense Technologies Inc
Application granted granted Critical
Publication of ATE309345T1 publication Critical patent/ATE309345T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0093—Oxidoreductases (1.) acting on CH or CH2 groups (1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT97932690T 1996-08-02 1997-08-01 Antitumor antisense sequenzen gegen h1 und r2 verbindungen von ribonukleotide reductase ATE309345T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2304096P 1996-08-02 1996-08-02
US3995997P 1997-03-07 1997-03-07
PCT/CA1997/000540 WO1998005769A2 (en) 1996-08-02 1997-08-01 Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase

Publications (1)

Publication Number Publication Date
ATE309345T1 true ATE309345T1 (de) 2005-11-15

Family

ID=26696655

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97932690T ATE309345T1 (de) 1996-08-02 1997-08-01 Antitumor antisense sequenzen gegen h1 und r2 verbindungen von ribonukleotide reductase

Country Status (12)

Country Link
US (1) US5998383A (cg-RX-API-DMAC10.html)
EP (1) EP0917569B1 (cg-RX-API-DMAC10.html)
JP (1) JP4301576B2 (cg-RX-API-DMAC10.html)
CN (1) CN1189562C (cg-RX-API-DMAC10.html)
AT (1) ATE309345T1 (cg-RX-API-DMAC10.html)
AU (1) AU738592C (cg-RX-API-DMAC10.html)
CA (1) CA2262776C (cg-RX-API-DMAC10.html)
DE (1) DE69734589T2 (cg-RX-API-DMAC10.html)
ES (1) ES2256893T3 (cg-RX-API-DMAC10.html)
IL (2) IL128124A0 (cg-RX-API-DMAC10.html)
NZ (1) NZ333802A (cg-RX-API-DMAC10.html)
WO (1) WO1998005769A2 (cg-RX-API-DMAC10.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
JP2000513230A (ja) * 1996-07-01 2000-10-10 エイ． ライト，ジム ハウスキーピング遺伝子の非翻訳領域由来のオリゴヌクレオチドおよび細胞増殖を調節するためのその使用方法
US6593305B1 (en) * 1996-08-02 2003-07-15 Genesense Technologies Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
CN1256632A (zh) * 1997-03-19 2000-06-14 吉倪塞思技术公司 利用核糖核苷酸还原酶r1抑制恶性肿瘤
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
EP1584681A3 (en) * 1997-07-10 2005-11-09 GeneSense Technologies Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
US6610539B1 (en) * 1997-07-10 2003-08-26 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
ES2374534T3 (es) * 1998-03-20 2012-02-17 Commonwealth Scientific And Industrial Research Organisation Control de la expresión de genes.
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
EP2314700A1 (en) * 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US6121000A (en) * 1999-02-11 2000-09-19 Genesense Technologies, Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
US6642033B1 (en) * 1999-07-20 2003-11-04 V.I. Technologies, Inc. Nucleic acids for detecting parvovirus and methods of using same
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
CN1301816A (zh) * 1999-12-27 2001-07-04 上海博德基因开发有限公司 一种新的多肽——核苷酸还原酶10和编码这种多肽的多核苷酸
AU2001240375A1 (en) * 2000-03-17 2001-10-03 Benitec Australia Limited Genetic silencing
US20020132257A1 (en) * 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
DE10131148A1 (de) * 2001-06-28 2003-01-16 I P L Internat Pharmaceutics L Xenogene Oligo- oder/und Polyribonukleotide als Mittel zur Behandlung von malignen Tumoren
WO2004070033A1 (en) 2003-02-10 2004-08-19 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
CA2524255C (en) * 2003-03-21 2014-02-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
US20070274947A1 (en) * 2003-05-21 2007-11-29 Young Aiping H Antisense Oligonucleotides Directed to Ribonucleotide Reductase R1 and Uses Thereof in the Treatment of Cancer
WO2004106518A1 (en) * 2003-05-31 2004-12-09 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
BRPI0415771A (pt) 2003-10-23 2006-12-26 Illumigen Biosciences Inc detecção de mutações em um gene associado à resistência a infecção viral, oas1
US20080311126A1 (en) * 2004-01-12 2008-12-18 Genesense Technologies, Inc Antisense Oligonucleotides Directed to Ribonucleotide Reducatase R2 and Uses Thereof in Combination Therapies for the Treatment of Cancer
EP1744761A4 (en) * 2004-04-28 2010-01-13 Molecules For Health Inc METHOD FOR THE TREATMENT OR PREVENTION OF RESTENOSIS AND OTHER PROLIFERATIVE VASCULAR DISORDER
EP1784501B1 (en) * 2004-05-14 2015-11-18 Rosetta Genomics Ltd VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF
US7968762B2 (en) * 2004-07-13 2011-06-28 Van Andel Research Institute Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
US20080255065A1 (en) * 2004-08-18 2008-10-16 Genesense Technologies, Inc. Small Interfering Rna Molecules Against Ribonucleotide Reductase and Uses Thereof
US20060185027A1 (en) * 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
ATE541928T1 (de) * 2005-03-31 2012-02-15 Calando Pharmaceuticals Inc Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
US9526707B2 (en) * 2007-08-13 2016-12-27 Howard L. Elford Methods for treating or preventing neuroinflammation or autoimmune diseases
US20100204305A1 (en) * 2007-12-11 2010-08-12 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
BRPI0820722A2 (pt) 2007-12-20 2015-06-16 Novartis Ag Derivados de tiazol usados como inibidores de pi 3 cinases
WO2010027279A2 (en) * 2008-09-04 2010-03-11 Genesis Research And Development Corporation Limited Compositions and methods for the treatment and prevention of neoplastic disorders
EP2727996A1 (en) 2008-11-06 2014-05-07 The Johns-Hopkins University Treatment of chronic inflammatory respiratory disorders with NP1 inhibitors
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
WO2012052258A1 (en) * 2010-10-18 2012-04-26 Arrowhead Research Corporation Compositions and methods for inhibiting expression of rrm2 genes
US8987257B2 (en) 2011-01-31 2015-03-24 Novartis Ag Heterocyclic derivatives
PT2771342T (pt) 2011-10-28 2016-08-17 Novartis Ag Derivados de purina e o seu uso no tratamento de doença
EP2849756A1 (en) 2012-05-16 2015-03-25 Novartis AG Dosage regimen for a pi-3 kinase inhibitor
WO2015083101A1 (en) 2013-12-06 2015-06-11 Novartis Ag Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
AU2016347881A1 (en) 2015-11-02 2018-05-10 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
EP0690869A1 (en) * 1993-03-23 1996-01-10 The Board Of Trustees Of The Leland Stanford Junior University Cellular regulation with riboregulators

Also Published As

Publication number Publication date
ES2256893T3 (es) 2006-07-16
EP0917569A2 (en) 1999-05-26
US5998383A (en) 1999-12-07
CA2262776A1 (en) 1998-02-12
JP2000517167A (ja) 2000-12-26
JP4301576B2 (ja) 2009-07-22
IL128124A (en) 2006-12-31
EP0917569B1 (en) 2005-11-09
CN1189562C (zh) 2005-02-16
DE69734589D1 (de) 2005-12-15
WO1998005769A3 (en) 1998-06-25
AU738592C (en) 2002-07-25
AU738592B2 (en) 2001-09-20
DE69734589T2 (de) 2006-08-10
CN1231694A (zh) 1999-10-13
NZ333802A (en) 2001-09-28
CA2262776C (en) 2005-03-08
IL128124A0 (en) 1999-11-30
AU3617597A (en) 1998-02-25
WO1998005769A2 (en) 1998-02-12

Similar Documents

Publication Publication Date Title
ATE309345T1 (de) Antitumor antisense sequenzen gegen h1 und r2 verbindungen von ribonukleotide reductase
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
EP0977767A4 (en) AMINOOXY MODIFIED OLIGONUCLEOTIDES
NO20014058D0 (no) TRPM-2 antisense-terapi
ATE346918T1 (de) Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
DK0731835T3 (da) Antisense-oligonukleotider med tumorigenicitetshæmmende virkning
EP0804563A4 (en) Antisense oligonucleotide generators
DK0664836T3 (da) Fremgangsmåde til sekventering af syntetiske oligonukleotider indeholdende ikke-phosphodiesterbindingsled mellem nukleotiderne
KR960701077A (ko) 올리고누클레오티드 알킬포스포네이트 및 알킬포스포노티오에이트(oligonucleotide alkylphosphonates and alkylphosphonothioates)
TWI255854B (en) Baculovirus containing minimal CMV promoter
PL328639A1 (en) Synthesis of p5' phosphoamidane oligonucleotides n3'
ATE216705T1 (de) Antisense-oligonukleotidmodulation der raf- genexpression
AU8771398A (en) Novel hiv-specific synthetic oligonucleotides and methods of their use
WO2001047944A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
BR0008788A (pt) Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase
EP1123414A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF INTEGRIN ALPHA 4
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO1999028439A3 (fr) Erythrovirus et ses applications
NO965017L (no) Oligonukleotider med anti-cytomegalovirus aktivitet
WO2001040521A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2001048245A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
ATE332981T1 (de) Einzelsträngige oligonukleotide, sonden, primer und ein vefahren zur detektion von spirochaeten
Abdula Silencing the code
WO2000029622A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2001038586A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties